Lonafarnib is under clinical development by Eiger BioPharmaceuticals and currently in Phase III for Hepatitis D. According to GlobalData, Phase III drugs for Hepatitis D have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lonafarnib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lonafarnib overview

Lonafarnib (Zokinvy) is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. It is formulated as hard gelatin capsules for oral route of administration. Zokinvy is indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above to reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome and for treatment of processing-deficient Progeroid Laminopathies with either Heterozygous LMNA mutation with progerin-like protein accumulation or Homozygous or compound heterozygous ZMPSTE24 mutations. Lonafarnib (Sarasar, SCH 66336) is under development for the treatment of Hepatitis D, brain tumors such as glioblastoma multiforme and gliosarcoma. It is a synthetic tricyclic derivative of carboxamide. Lonarfanib binds to and inhibits farnesyl transferase. It was also under development for the treatment of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, non-small cell lung cancer, squamous cell carcinoma of the head and neck, myelodysplastic syndrome and chronic myelomonocytic leukemia (CMML), adenocarcinoma of prostate cancer and metastatic breast cancer.

Eiger BioPharmaceuticals overview

Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as lonafarnib and lambda which are used for the treatment of hepatitis delta virus infection; exendin 9-39 post-bariatric hypoglycemia; ubenimex for lymphedema and pulmonary arterial hypertension. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company also offers post-bariatric hypoglycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.

For a complete picture of Lonafarnib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.